Abstract
The mixed lineage leukemia (MLL) gene at chromosome band 11q23 is commonly involved in reciprocal translocations that are detected in acute leukemias. Evidence suggests that the resulting MLL fusion genes contribute to leukemogenesis. AF9 is a common MLL fusion partner in acute myeloid leukemia. The AF9 protein functions as a transcriptional activator in artificial reporter gene assays and a structurally related protein in yeast, ANC1/TFG3, is a component of the SWI/SNF complex. Apart from these observations, little is known about the biologic function of AF9 in mammals. We have found that a recently described transcriptional repressor, BCL-6 corepressor (BCoR), interacts with the carboxy-terminus of AF9. The interaction of AF9 with BCoR has been confirmed by independent in vitro and in vivo protein-binding studies. The BCoR gene is expressed as several alternatively spliced transcripts. AF9 only binds BCoR isoforms that contain a unique 34 aa sequence located in the mid-portion of the protein. In artificial reporter gene assays, a BCoR isoform that binds AF9 efficiently suppresses AF9 transcriptional activity, while a nonbinding isoform does not. These results indicate that different isoforms of BCoR have unique biologic properties and that cell function may be partly determined by the different isoforms that are present within the cell.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace Jr AJ and Tkachuk DC . (1999). Mol. Cell. Biol., 19, 7050–7060.
Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR and Korsmeyer SJ . (2002). Nat. Genet., 30, 41–47.
Ayton PM and Cleary ML . (2001).Oncogene, 20, 5695–5705.
Cairns BR, Henry NL and Kornberg RD . (1996). Mol. Cell. Biol., 16, 3308–3316.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y . (2002). Science, 298, 1039–1043.
Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y and Rabbitts TH . (2002). Mol. Cell. Biol., 22, 7313–7324.
Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie ANJ, King G and Rabbits TH . (1996). Cell, 85, 853–861.
Djabali M, Selleri L, Parry P, Bower M, Young BD and Evans GA . (1992). Nat. Genet., 2, 113–118.
Downing JR and Look AT . (1996). Molecular Genetics and Therapy of Leukemia. Kluwer Academic Publishers: Boston, MA.
Erfruth F, Hemenway C, de Erkenez A and Domer P . (2000). Blood, 96, 700a.
GarcÃa-Cuéllar MP, Zilles O, Schreiner SA, Birke M,, Winkler TH and Slany RK . (2001). Oncogene, 20, 411–419.
Gecz J, Gedeon AK, Sutherland GR and Mulley JC . (1996). Nat. Genet., 13, 105–108.
Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM and Canaani E . (1992). Cell, 71, 701–708.
Gu Y, Shen Y, Gibbs R and Nelson DL . (1996). Nat. Genet., 13, 109–113.
Hemenway CS, de Erkenez AC and Gould GCD . (2001). Oncogene, 20, 3798–3805.
Henry NL, Campbell AM, Feaver WJ, Poon D, Weil PA and Kornberg RD . (1994). Genes Dev., 8, 2868–2878.
Hess JL, Yu BD, Li B, Hanson R and Korsmeyer SJ . (1997). Blood, 90, 1799–1806.
Henry NL, Sayre MH and Kornberg RD . (1992). J. Biol. Chem., 267, 23388–23392.
Huynh KD, Fischle W, Verdin E and Bardwell V . (2000). Genes Dev., 14, 1810–1823.
Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M and Hayashi Y . (1997). Blood, 90, 4699–4704.
Joh T, Kagami Y, Yamamoto K, Segawa T, Takizawa J, Takahashi T, Ueda R and Seto M . (1996). Oncogene, 13, 1945–1953.
Kuwada N, Kimura F, Matsumura T, Yamashita T, Nakamura Y, Wakimoto N, Ikeda T, Sato K and Mtoyoshi K . (2001). Cancer Res., 61, 2665–2669.
Mahmoudi T and Verrijzer CP . (2001). Oncogene, 20, 3055–3066.
Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM and Canaani E . (1993). Proc. Natl. Acad. Sci. USA, 90, 4631–4635.
Odero MD, Zeleznik-Le NJ, Chinwalla V and Rowley JD . (2000). Genes Chromosomes Cancer, 29, 333–338.
Ono R, Taki T, Taketani T, Kawaguchi H, Taniwaki M, Okamura T, Kawa K, Hanada R, Kobayashi M and Hayashi Y . (2002). Cancer Res., 62, 333–337.
Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro Jr J, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM and Williams DL . (1989). N. Engl. J. Med., 321, 136–142.
Rowley JD . (1993). Semin. Cancer Biol., 4, 377–385.
Rubnitz JE, Morrissey J, Savage PA and Cleary ML . (1994). Blood, 84, 1747–1752.
Shao Z, Raible F, Mollaaghababa R, Guyon J, Wu C, Bender W and Kingston RE . (1999). Cell., 98, 37–46.
Shilatifard A, Lane WS, Jackson KW, Conaway RC and Conaway JW . (1996). Science, 271, 1873–1876.
Slany RK, Lavau C and Cleary ML . (1998). Mol. Cell. Biol., 18, 122–129.
Smith MA, Rubinstein L and Ungerleider RS . (1994). Med. Pediatr. Oncol., 23, 86–98.
Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD and Zeleznik-Le NJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 8732–8737.
Tkachuk D, Kohler S and Cleary ML . (1992). Cell, 71, 691–700.
van der Vlag J and Otte A . (1999). Nat. Genet., 23, 474–478.
Welch MD and Drubin DG . (1994). Mol. Biol. Cell, 5, 617–632.
Yu BD, Hess JL, Horning SE, Brown GAJ and Korsmeyer SJ . (1995). Nature, 378, 505–508.
Acknowledgements
This work was supported in part by National Institutes of Health Grant CA78318 and by developmental funds of the Tulane Cancer Center. We thank Roxanne Reger and the Tulane Center for Gene Therapy for technical assistance with digital deconvolution microscopy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Srinivasan, R., Erkenez, A. & Hemenway, C. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor. Oncogene 22, 3395–3406 (2003). https://doi.org/10.1038/sj.onc.1206361
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206361
Keywords
This article is cited by
-
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
Journal of Hematology & Oncology (2022)
-
RNA binding proteins in MLL-rearranged leukemia
Experimental Hematology & Oncology (2022)
-
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Journal of Hematology & Oncology (2021)
-
Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX
Scientific Reports (2021)
-
Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis
Nature Communications (2019)